Pregled bibliografske jedinice broj: 547074
Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157
Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157 // Current medicinal chemistry, 19 (2012), 1; 126-132 doi:10.2174/092986712803414015 (međunarodna recenzija, pregledni rad, znanstveni)
CROSBI ID: 547074 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Focus on Ulcerative Colitis : Stable Gastric Pentadecapeptide BPC 157
Autori
Sikirić, Predrag ; Seiwerth, Sven ; Ručman, Rudolf ; Turković, Branko ; Stančić-Rokotov, Dinko ; Brčić, Luka ; Sever, Marko ; Kliček, Robert ; Radić, Božo ; Drmić, Domagoj ; Ilić, Spomenko ; Kolenc, Danijela ; Stambolija, Vasilije ; Zoričić, Zoran ; Vrčić, Hrvoje ; Šebečić, Božidar
Izvornik
Current medicinal chemistry (0929-8673) 19
(2012), 1;
126-132
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni
Ključne riječi
BPC 157; intestinal anastomosis; short bowel; colocutaneous fistulas; inflammatory bowel disease
Sažetak
Stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, M.W. 1419) may be the new drug stable in human gastric juice, effective both in the upper and lower GI tract, and free of side effects. BPC 157, in addition to an antiulcer effect efficient in therapy of inflammatory bowel disease (IBD) (PL 14736) so far only tested in clinical phase II, has a very safe profile, and exhibited a particular wound healing effect. It also has shown to interact with the NO-system, providing endothelium protection and angiogenic effect, even in severely impaired conditions (i.e., it stimulated expression of early growth response 1 gene responsible for cytokine and growth factor generation and early extracellular matrix (collagen) formation (but also its repressor nerve growth factor 1- A binding protein-2)), important to counteract severe complications of advanced and poorly controlled IBD. Hopefully, the lessons from animal studies, particularly advanced intestinal anastomosis healing, reversed short bowel syndrome and fistula healing indicate BPC 157’s high significance in further IBD therapy. Also, this supportive evidence (i.e., no toxic effect, limit test negative, LD1 not achieved, no side effect in trials) may counteract the problems commonly exercised in the use of peptidergic agents, particularly those used on a long-term basis
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti, Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1083570-3635 - Pentadekapeptid BPC 157 - daljnja istraživanja (Sikirić, Predrag, MZOS ) ( CroRIS)
108-1083570-3611 - Pentadekapeptid BPC 157- učinkovita terapija ozljeda mišića i tetive (Šebečić, Božidar, MZOS ) ( CroRIS)
108-1083570-3634 - Genetička istraživanja učinka BPC-157 na mikroorganizmima (Džidić, Senka, MZOS ) ( CroRIS)
108-1083570-3643 - Kvantitativna analiza i prijenos slike u patologiji (Seiwerth, Sven, MZOS ) ( CroRIS)
108-1080321-0389 - Utjecaj pentadekapeptida BPC 157 na ženski urogenitalni sustav (Vrčić, Hrvoje, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Spomenko Ilić
(autor)
Zoran Zoričić
(autor)
Branko Turković
(autor)
Sven Seiwerth
(autor)
Hrvoje Vrčić
(autor)
Luka Brčić
(autor)
Robert Kliček
(autor)
Dinko Stančić-Rokotov
(autor)
Predrag Sikirić
(autor)
Danijela Kolenc
(autor)
Božidar Šebečić
(autor)
Marko Sever
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- MEDLINE